Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AP301 in hyperphosphatemia in dialysis patients
NCT07030595Phase 3Completed
- Sponsor
- Alebund Pharmaceuticals
- Start
- Jun 2023
- Primary completion
- Oct 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of AP301 in hyperphosphatemia (3 arms), sponsored by Alebund Pharmaceuticals. Primary endpoints: Change in serum phosphorus levels between AP301 and AP301 low dose groups at 27 weeks and Change in serum phosphorus levels between AP301 and sevelamer carbonate groups at 12 weeks. Started Jun 2023; status: completed.
02
Drugs
AP301
03
Conditions
hyperphosphatemia
Beyond the preview
Go deeper on NCT07030595.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07030595.